A British biotech based in Cambridge, England, raised $86 million to advance an antibody drug designed to deplete protein deposits in people with amyloidosis.
The company, called Immutrin, was co-founded by Gregory Winter. He won …
There’s a reason lots of companies are working on GLP-1-based drugs for obesity: The other stuff tends not to work. The latest biotech to learn
Plus, news about Astellas’ setidegrasib and Anavex: 📈 Kodiak’s eye drug win: The biotech’s experimental drug Zenkuda, whose scientific name is tarcocimab tedromer, beat a
A March study in Nature Medicine showed that AI designed for therapy can deliver better care than human clinicians in a specific type of therapy.
Who knows what’s going to happen to the Advisory Committee on Immunization Practices? Former member Robert Malone suggested in a string of social media posts
A machine learning algorithm could serve as a pre-screen for hepatocellular carcinoma that identifies patients missed by current narrow guidance.
A British biotech based in Cambridge, England, raised $86 million to advance an antibody drug designed to deplete protein deposits in people with amyloidosis.
The company, called Immutrin, was co-founded by Gregory Winter. He won …